At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Erlotinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Erlotinib, An Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
In Brief
A Phase 2 clinical trial evaluating Erlotinib for Metastatic Skin Squamous Cell Carcinoma and Recurrent Skin Squamous Cell Carcinoma. Completed, enrolled 42 participants across 1 site.
Detailed Summary
This phase II trial studies how well erlotinib works in treating participants with skin squamous cell carcinoma that has spread to other places in the body or has come back. Drugs used in chemotherapy, such as erlotinib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartMar 2011
Primary CompletionMay 2019
TodayJul 2026
First PostedSep 9, 2010
Enrollment StartMar 10, 2011
Primary CompletionMay 1, 2019
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 15.8 years ago
Interventions
Erlotinibdrug
Given PO